Overview

Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies

Status:
Terminated

Trial end date:
2020-06-22

Target enrollment:

Participant gender:

Summary

Multicenter, randomized, open-label, 2-arm, parallel-group, phase III study whose goal is to assess the efficacy and safety profile of bone-targeted treatments (Arm A: denosumab or zoledronic acid) versus the control arm (Arm B: no specific treatment) in patients with bone metastases under targeted therapy for Metastatic Renal Cell Carcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

Centre Leon Berard

Treatments:

Denosumab
Diphosphonates
Zoledronic Acid